Last updated: June 23, 2026
Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA Inc., case number 1:18-cv-00651, is a federal patent litigation matter tied to Vanda’s FDA-adjacent IP strategy for its key branded psychiatry asset. The docket indicates a Paragraph IV-style posture typical of generic-entry disputes, with Vanda asserting infringement of one or more Orange Book-listed patents and Teva defending via non-infringement and invalidity positions, plus typical procedural and remedies arguments.
What litigation outcome matters most: the case affects near-term generic launch risk, licensing leverage, and the remaining enforceable term of the asserted patent(s). Without the asserted-patent list, claim construction orders, and final judgment docket entries, a complete, accurate patent-by-patent analysis cannot be produced from the case caption alone.
What patents did Vanda assert in Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. (1:18-cv-00651)?
Answer: Not determinable from the case caption and docket identifier alone. A correct infringement map depends on the specific Orange Book patents named in the complaint and whether the asserted claims focus on drug substance, composition, formulation, method of use, or dosing regimen.
Which Orange Book listing is implicated
Fanapt (iloperidone) is the most common Vanda-branded US product associated with generic entry challenges. In these matters, Vanda typically lists:
- drug substance and/or polymorph and process patents,
- composition/formulation patents,
- method-of-treatment patents,
- and sometimes specific dosing/administration patents.
What claim categories usually drive outcomes
In iloperidone and comparable psychiatry generic challenges, infringement disputes often center on:
- whether the generic product uses the claimed formulation or manufacturing method,
- whether the generic meets the claimed dosing regimen in labeling,
- and whether the asserted claims are anticipated/obvious over prior art.
What is the timeline of filings, motions, and key docket events in 1:18-cv-00651?
Answer: Not determinable from the provided identifier alone. A precise timeline requires docket-stamped events (complaint filing date, answer date, scheduling order dates, Markman date, summary judgment orders, claim construction ruling dates, trial dates, and any settlement or dismissal entries).
Typical event structure in this docket type
For Paragraph IV Hatch-Waxman suits, the docket usually includes:
- complaint and infringement contentions,
- Teva’s invalidity and non-infringement defenses,
- protective order and discovery,
- Markman/claim construction hearing,
- summary judgment motion practice,
- final disposition or settlement with stipulated dismissal.
Actionability for business decisions
The decisive questions for investors and licensing teams are:
- Did Vanda secure an injunction or final judgment of infringement?
- Did Teva get a dismissal without prejudice that preserves future workarounds?
- Was the case settled with a launch date or covenant not to sue?
- What patents remained enforceable post-disposition?
How did Teva defend against Vanda’s infringement claims in 1:18-cv-00651?
Answer: Not determinable from the provided identifier alone. In these litigations, Teva’s defense commonly includes:
- invalidity for anticipation or obviousness,
- non-infringement (product not practicing the claimed features),
- prosecution history estoppel or claim scope disputes,
- and procedural defenses related to standing, sufficiency of pleadings, or FDA listing mechanics.
What defense angles typically matter most
- Invalidity: whether the asserted claims are vulnerable to prior art product disclosures, formulation examples, or dosing references.
- Non-infringement: whether Teva’s formulation composition and manufacturing process differ from the asserted claims’ critical limitations.
- Remedies: whether any potential injunction is limited by later-expiring patents in a family or by FDA label noncongruence.
When does the asserted patent(s) lose exclusivity, and what is the generic launch risk window?
Answer: Cannot be calculated without the asserted patent numbers and their expiration dates (including any PTA/PTE and patent-term adjustments). Generic launch risk hinges on:
- the expiration of the last-to-expire asserted patent,
- whether any additional non-infringement judgment or covenant changes effective exclusivity,
- and whether the case ended via settlement with an agreed entry date.
What to compute once patent numbers are known
- Patents’ end-of-term dates (including PTA/PTE),
- earliest possible FDA approval date for Teva’s ANDA (if permitted by court outcomes),
- 30-month stay status and any extensions or lifting events tied to litigation milestones.
What is the Orange Book status of the patents involved in Vanda v. Teva (1:18-cv-00651)?
Answer: Not determinable from the docket identifier alone. Orange Book status is patent-number specific and requires:
- the drug product (NDA/ANDA entry),
- the listed patent(s),
- patent expiry and exclusivity classification (drug substance, drug product, method-of-use),
- and whether patents were withdrawn or amended during the life of the listing.
Did Teva file a Paragraph IV certification, and how did that drive the case?
Answer: Not determinable from the provided identifier alone. Paragraph IV disputes are the usual procedural engine, but the record must be checked for:
- the ANDA number,
- the certification(s) type (Paragraph III vs IV),
- the specific patents alleged to be invalid or not infringed,
- and the timing of FDA ANDA submission.
Why certification type changes strategy
- A Paragraph IV triggers a 30-month stay and immediate litigation cadence.
- Certification to non-infringement/invalidity changes settlement dynamics and potential launch date structures.
What settlement terms or dismissal posture affected Teva’s ability to launch?
Answer: Not determinable from the provided identifier alone. Settlement and stipulated dismissal terms typically include:
- an agreed launch date,
- scope limitations (label carve-outs),
- covenant-not-to-sue boundaries for unasserted patents,
- and sometimes payment/royalty structures.
Business relevance
For licensing and competitive strategy, the questions are:
- Does the settlement resolve all asserted patents or only some?
- Is there a stipulated carve-out that preserves Vanda’s ability to sue later?
- Are there remaining “blocking” patents not asserted in this case?
How strong is Vanda’s patent estate for the relevant iloperidone product family?
Answer: Not determinable without the asserted patent numbers and their family structure. Strength depends on:
- claim breadth and remaining term,
- prior art resistance profile,
- litigation history (prior validity/infringement outcomes),
- and whether the family has layered claims across formulation and method-of-use categories.
What patent strength metrics usually drive outcomes
- Number of independent claims surviving key motions,
- how many claim limitations are tied to demonstrable product features,
- prior art saturation against those limitations,
- and whether claim scope is narrowed by construction.
How does Vanda v. Teva (1:18-cv-00651) compare with other branded psychiatry Hatch-Waxman litigations?
Answer: Not determinable from the provided identifier alone. Comparison requires case-specific outcomes, asserted patent types, and any appellate history.
Common patterns in psychiatry generic disputes
- formulation patents often face obviousness attacks,
- method-of-use claims often hinge on label and practice,
- process patents depend on proof of manufacturing steps.
What generic entry risks exist for Teva and other filers if Vanda loses or settles?
Answer: Not determinable without knowing:
- whether any asserted patents were found invalid or not infringed,
- whether the dismissal was with prejudice,
- and whether Teva gained design-around freedom extending to other ANDA filers.
Risk framework
- If the asserted patents are invalidated: rapid follow-on generic launches increase.
- If infringement stands: design-around attempts likely shift to different formulations or labeling.
- If settlement includes an early entry date: competition accelerates even if patents remain on the Orange Book until expiration.
Key takeaways
- Case specificity is the gating factor. The docket identifier 1:18-cv-00651 and party names are insufficient to produce a patent-by-patent, timeline-driven litigation analysis.
- Decisive business inputs are absent from the provided data. Missing: asserted patent numbers, Orange Book listing mapping, key docket events, claim construction results, and final disposition terms.
- Strategic impact still exists. As with other Hatch-Waxman disputes, the litigation outcome would typically determine Teva’s launch timing and Vanda’s enforceable exclusivity position.
FAQs
- What does a “Teva Pharmaceuticals USA, Inc.” branded-drug Hatch-Waxman suit typically seek to overturn?
- How do claim construction rulings usually affect generic non-infringement defenses in method-of-use cases?
- What settlement mechanisms most often control the actual first-to-market date in generic entry disputes?
- How can unasserted Orange Book patents still block entry after a settlement or dismissal?
- What is the usual impact of PTA/PTE on when an Orange Book-listed patent truly expires?
References (APA)
- Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc., No. 1:18-cv-00651 (Docket).
